The addition of ipilimumab (Yervoy) to nivolumab and relatlimab-rmbw (Opdualag) has generated high response rates and promising survival outcomes as a first-line treatment for patients with advanced melanoma in the phase 1/2 RELATIVITY-048 trial (NCT03459222), signifying the viability of triplet checkpoint blockade for this patient population, according to Ankit Mangla, MD. However, larger studies are needed to confirm the efficacy and safety of this approach for use in the frontline setting.
Clinical Trials
Tumor-infiltrating lymphocyte therapy marks a milestone in cancer treatment, researchers say
The recent U.S. Food and Drug Administration approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, marks a significant breakthrough in cancer therapy. In a new commentary published in Cancer Cell, Moffitt Cancer Center scientists provide a comprehensive overview of the therapy’s development and highlight its transformative potential.
First-of-its-kind clinical trial eliminates or shrinks melanoma tumors in 70% of patients
A clinical trial has shown that a new drug combination utilized before surgery completely eliminated or shrunk melanoma tumors in 70% of trial participants.
Daromun Shows Promising Results in Reducing Melanoma Recurrence and Metastasis
It is injected directly into the tumor, but its effectiveness has a broader range of action that also prevents the appearance of distant metastases.